PMID- 16971810
OWN - NLM
STAT- MEDLINE
DCOM- 20061114
LR  - 20201226
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 29
IP  - 5
DP  - 2006 Sep-Oct
TI  - Dendritic cells loaded with killed allogeneic melanoma cells can induce objective 
      clinical responses and MART-1 specific CD8+ T-cell immunity.
PG  - 545-57
AB  - Dendritic cells (DCs) loaded with killed allogeneic tumors can cross-prime 
      tumor-specific naive CD8 T cells in vitro, thereby providing an option to 
      overcome human leukocyte antigen restriction inherent to loading DC vaccines with 
      peptides. We have vaccinated 20 patients with stage IV melanoma with autologous 
      monocyte-derived DCs loaded with killed allogeneic Colo829 melanoma cell line. 
      DCs were generated by culturing monocytes with granulocyte macrophage-colony 
      stimulating factor (granulocyte macrophage-colony stimulating factor) and 
      interleukin (IL-4) and activated by additional culture with tumor necrosis factor 
      and CD40 ligand. A total of 8 vaccines were administered at monthly intervals. 
      The first patient was accrued December 2002 and the last November 2003. Fourteen 
      patients were alive at 12 months, 9 patients were alive at 24 months, and 8 
      patients are alive as of January 2006. The estimated median overall survival is 
      22.5 months with a range of 2 to 35.5 months. Vaccinations were safe and 
      tolerable. They induced, in 2 patients who failed previous therapy, durable 
      objective clinical responses, 1 complete regression (CR) and 1 partial regression 
      (PR) lasting 18 and 23 months, respectively. Three out of 13 analyzed patients 
      showed T-cell immunity to melanoma antigen recognized by autologous T cells 
      (MART-1) tissue differentiation antigen. Two of 3 patients showed improved immune 
      function after vaccinations demonstrated by improved secretion of interferon 
      (IFN)-gamma or T-cell proliferation in response to MART-1 derived peptides. In 
      one of these patients, vaccination led to elicitation of CD8 T-cell immunity 
      specific to a novel peptide-derived from MART-1 antigen, suggesting that 
      cross-priming/presentation of melanoma antigens by DC vaccine had occurred. Thus, 
      the present results justify the design of larger follow-up studies to assess the 
      clinical response to DC vaccines loaded with killed allogeneic tumor cells in 
      patients with metastatic melanoma.
FAU - Palucka, Anna K
AU  - Palucka AK
AD  - Baylor Institute for Immunology Research, Sammons Cancer Center, 3434 Live Oak, 
      Dallas, TX 75204, USA. karolinp@baylorhealth.edu
FAU - Ueno, Hideki
AU  - Ueno H
FAU - Connolly, John
AU  - Connolly J
FAU - Kerneis-Norvell, Fabienne
AU  - Kerneis-Norvell F
FAU - Blanck, Jean-Philippe
AU  - Blanck JP
FAU - Johnston, Dennis A
AU  - Johnston DA
FAU - Fay, Joseph
AU  - Fay J
FAU - Banchereau, Jacques
AU  - Banchereau J
LA  - eng
GR  - CA 085540/CA/NCI NIH HHS/United States
GR  - CA 89440/CA/NCI NIH HHS/United States
GR  - P01 CA 84512/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/adverse effects/*therapeutic use
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Cross-Priming
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/cytology/*immunology
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Interferon-gamma/metabolism
MH  - MART-1 Antigen
MH  - Melanoma/immunology/pathology/*therapy
MH  - Middle Aged
MH  - Monocytes/cytology/immunology
MH  - Neoplasm Metastasis
MH  - Neoplasm Proteins/*immunology
MH  - Peptides/immunology
MH  - Skin Neoplasms/immunology/pathology/*therapy
MH  - Survival Rate
MH  - Transplantation, Homologous
EDAT- 2006/09/15 09:00
MHDA- 2006/11/15 09:00
CRDT- 2006/09/15 09:00
PHST- 2006/09/15 09:00 [pubmed]
PHST- 2006/11/15 09:00 [medline]
PHST- 2006/09/15 09:00 [entrez]
AID - 00002371-200609000-00009 [pii]
AID - 10.1097/01.cji.0000211309.90621.8b [doi]
PST - ppublish
SO  - J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b.